Earnings Feed
Start Free
Home/Filings/4/0001601830-24-000221
4//SEC Filing

Michor Franziska 4

Accession 0001601830-24-000221

CIK 0001601830other
View on SEC.govCompany Profile

Filed

Nov 21, 7:00 PM ET

Accepted

Nov 22, 6:25 PM ET

Size

20.3 KB

Accession

0001601830-24-000221

Insider Transaction Report

Form 4
Period: 2024-11-20
RECURSION PHARMACEUTICALS, INC.RXRX
Michor Franziska
Director
Transactions
  • Award

    Stock Option (Right to Buy)

    2024-11-20+17,694→ 17,694 total
    Exercise: $6.64Exp: 2034-05-14→ Class A Common Stock (17,694 underlying)
  • Award

    Class A Common Stock

    2024-11-20+30,618→ 30,618 total
  • Award

    Class A Common Stock

    2024-11-20+15,335→ 45,953 total
  • Award

    Class A Common Stock

    2024-11-20+41,390→ 105,037 total
  • Award

    Class A Common Stock

    2024-11-20+17,694→ 63,647 total
  • Award

    Stock Option (Right to Buy)

    2024-11-20+30,670→ 30,670 total
    Exercise: $6.59Exp: 2033-05-02→ Class A Common Stock (30,670 underlying)
  • Award

    Stock Option (Right to Buy)

    2024-11-20+82,781→ 82,781 total
    Exercise: $6.04Exp: 2034-11-21→ Class A Common Stock (82,781 underlying)
  • Award

    Stock Option (Right to Buy)

    2024-11-20+15,286→ 15,286 total
    Exercise: $7.34Exp: 2033-05-16→ Class A Common Stock (15,286 underlying)
Footnotes (11)
  • [F1](1) Received in exchange for [] ordinary shares of Exscientia plc ("Exscientia") in connection with the acquisition of the entire issued and to be issued share capital of Exscientia by Recursion Pharmaceuticals, Inc. ("Recursion") on November 20, 2024 (the "Transaction"). The last closing price on The Nasdaq Stock Market prior to the effective time of the Transaction of (a) the American Depositary Shares ("ADSs") representing ordinary shares of Exscientia was $4.84 per ADS, and (b) Recursion's Class A common stock was $6.27 per share.
  • [F10]Received in the Transaction in exchange for a share option to acquire 22,894 Exscientia ordinary shares for $5.13 per share.
  • [F11]Represents a grant of options automatically granted pursuant to Recursion's Outside Director Compensation Policy. The shares subject to this option will vest and become exercisable as to 1/3rd of the shares subject to the award on the first three anniversaries of November 20, 2024, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates.
  • [F2]Represents restricted stock units ("RSUs") that were exchanged in connection with the Transaction, each RSU representing the right to receive one share of Class A common stock of Recursion. The RSUs vest in equal quarterly installments beginning on November 3, 2024 and continuing through May 3, 2026, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates.
  • [F3]Represents RSUs that were exchanged in connection with the Transaction, each RSU representing the right to receive one share of Class A common stock of Recursion. The RSUs will vest onMay 15, 2025, subject to the Reporting Person continuing to be a service provider through the applicable vesting date.
  • [F4]Represents a grant of restricted stock units automatically granted pursuant to Recursion's Outside Director Compensation Policy. The restricted stock units will vest as to 1/3rd of the shares subject to the award on the first three anniversaries of November 20, 2024, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates.
  • [F5]Options vest and become exercisable in equal quarterly installments over a three year period beginning May 3, 2023, subject to the Reporting Person continuing to be a service provider through the applicable vesting dates.
  • [F6]Received in the Transaction in exchange for a share option to acquire 39,683 Exscientia ordinary shares for $5.09 per share.
  • [F7]Options vest and become exercisable on May 17, 2024, subject to the Reporting Person continuing to be a service provider through the applicable vesting date.
  • [F8]Received in the Transaction in exchange for a share option to acquire 19,778 Exscientia ordinary shares for $5.67 per share.
  • [F9]Options vest and become exercisable on May 15, 2025, subject to the Reporting Person continuing to be a service provider through the applicable vesting date.

Documents

1 file

Issuer

RECURSION PHARMACEUTICALS, INC.

CIK 0001601830

→
Entity typeother

Related Parties

1
  • filerCIK 0002045159

Filing Metadata

Form type
4
Filed
Nov 21, 7:00 PM ET
Accepted
Nov 22, 6:25 PM ET
Size
20.3 KB
View on SEC.gov